Status:
COMPLETED
Noradrenalin vs Terlipressin in Hepatorenal Syndrome
Lead Sponsor:
University of Turin, Italy
Conditions:
Hepatorenal Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome
Detailed Description
Hepatorenal syndrome (HRS) is a major complication of cirrhosis; it is characterized by functional renal failure and poor prognosis. Arterial dilation is a key pathogenic event of HRS, leading to redu...
Eligibility Criteria
Inclusion
- Hepatorenal syndrome
- Age: 18-75 years
- Informed written consent
Exclusion
- Multinodular hepatocellular carcinoma (more than 3 nodules)
- Portal vein thrombosis
- Ongoing bacterial infection
- Ongoing or recent (less than one week) bleeding
- Cardio-pulmonary failure
- Coronary artery disease
- Peripheral artery disease
- Arterial hypertension
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00370253
Start Date
September 1 2006
End Date
September 1 2007
Last Update
April 11 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Giovanni Battista Hospital
Turin, Italy, 10126